Literature DB >> 22019035

Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapy.

Timur Mitin1, Ming-Hui Chen, Yuanye Zhang, Brian J Moran, Daniel E Dosoretz, Michael J Katin, Michelle H Braccioforte, Sharon A Salenius, Anthony V D'Amico.   

Abstract

PURPOSE: Black men present more frequently with high grade prostate cancer and are more likely to have diabetes mellitus. We evaluated whether there is an independent association between diabetes mellitus and the risk of high grade prostate cancer in men diagnosed with prostate cancer and treated with radiation therapy.
MATERIALS AND METHODS: A polychotomous logistic regression analysis was performed to evaluate whether a diagnosis of diabetes mellitus was associated with the odds of Gleason score 7 or 8-10 prostate cancer in a cohort of 16,286 men, adjusting for black race, advancing age, prostate specific antigen and digital rectal examination findings.
RESULTS: Black men (adjusted OR 1.84, 95% CI 1.08-3.13, p = 0.024) and nonblack men (adjusted OR 1.59, 95% CI 1.33-1.89, p <0.001) with diabetes were more likely to have Gleason score 8-10 vs 6 or less prostate cancer than nondiabetic men. However, this was not true for Gleason score 7 vs 6 or less prostate cancer. Black race was significantly associated with Gleason score 7 vs 6 or less prostate cancer in men without and with diabetes (adjusted OR 1.38, 95% CI 1.17-1.63, p <0.001 and 1.61, 95% CI 1.17-2.21, p = 0.003, respectively). Black race was also associated with Gleason score 8-10 vs 6 or less prostate cancer in men without and with diabetes (adjusted OR 1.36, 95% CI 1.01-1.83, p = 0.04 and 1.58, 95% CI 0.98-2.53, p = 0.06, respectively).
CONCLUSIONS: In a cohort of men undergoing radiotherapy for prostate cancer the diagnosis of diabetes mellitus was significantly associated with an increased risk of being diagnosed with Gleason score 8-10 prostate cancer independent of black race. Copyright Â
© 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22019035     DOI: 10.1016/j.juro.2011.07.072

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

1.  Statins and Finasteride Use Differentially Modify the Impact of Metformin on Prostate Cancer Incidence in Men with Type 2 Diabetes.

Authors:  Wang Chen-Pin; Hernandez Javier; Carlos Lorenzo; John R Downs; Ian M Thompson; Bradley Pollock; Donna Lehman
Journal:  Ann Transl Med Epidemiol       Date:  2014

2.  The association of diabetes and obesity with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study.

Authors:  Saira Khan; Jianwen Cai; Matthew E Nielsen; Melissa A Troester; James L Mohler; Elizabeth T H Fontham; Laura H Hendrix; Laura Farnan; Andrew F Olshan; Jeannette T Bensen
Journal:  Cancer Causes Control       Date:  2016-11-09       Impact factor: 2.506

3.  Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality.

Authors:  Daniel E Spratt; Chi Zhang; Zachary S Zumsteg; Xin Pei; Zhigang Zhang; Michael J Zelefsky
Journal:  Eur Urol       Date:  2012-12-14       Impact factor: 20.096

4.  Association between Types of Chronic Conditions and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Prostate Cancer.

Authors:  Amit D Raval; Suresh Madhavan; Malcolm D Mattes; Usha Sambamoorthi
Journal:  Popul Health Manag       Date:  2016-03-31       Impact factor: 2.459

5.  Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients.

Authors:  Donna M Lehman; Carlos Lorenzo; Javier Hernandez; Chen-Pin Wang
Journal:  Diabetes Care       Date:  2012-03-28       Impact factor: 19.112

6.  Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer.

Authors:  Jeffrey Shevach; Emily Jane Gallagher; Teena Kochukoshy; Victoria Gresia; Manpreet Brar; Matthew D Galsky; William K Oh
Journal:  Front Oncol       Date:  2015-06-15       Impact factor: 6.244

7.  Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.

Authors:  Yoko Tsutsumi; Takashi Nomiyama; Takako Kawanami; Yuriko Hamaguchi; Yuichi Terawaki; Tomoko Tanaka; Kunitaka Murase; Ryoko Motonaga; Makito Tanabe; Toshihiko Yanase
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

8.  Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories.

Authors:  Rhonda Arthur; Henrik Møller; Hans Garmo; Lars Holmberg; Pår Stattin; Håkan Malmstrom; Mats Lambe; Niklas Hammar; Göran Walldius; David Robinson; Ingmar Jungner; Mieke Van Hemelrijck
Journal:  Cancer Med       Date:  2016-02-29       Impact factor: 4.452

Review 9.  Prostate carcinogenesis with diabetes and androgen-deprivation-therapy-related diabetes: an update.

Authors:  Noboru Hara
Journal:  Exp Diabetes Res       Date:  2012-06-26

10.  Urinary melatonin-sulfate/cortisol ratio and the presence of prostate cancer: A case-control study.

Authors:  Shu-Yu Tai; Shu-Pin Huang; Bo-Ying Bao; Ming-Tsang Wu
Journal:  Sci Rep       Date:  2016-07-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.